Start here
Where are you in your journey?
Choose the path that fits today. We’ll take you to the most useful discussions.
- GLP-1 medication Zepbound, Wegovy, access, side effects, progress, and support.
- Before surgery Compare procedures, plan ahead, and get honest pre-op answers.
- Post-op Recovery, food stages, symptoms, and support.
- Long-term Regain, labs, habits, and life after the honeymoon.
- Revision Explore revision options, complications, and next steps.
Archive, page 4
Clear, source-linked updates on weight-loss surgery and obesity medicines for patients and clinicians.
Patient-first briefs. Linked sources. Evidence without hype.
Older briefs
Page 4
-
Expert panel proposes common measures for weight recurrence after bariatric surgery
A modified Delphi project developed shared terms and thresholds for assessing suboptimal response after metabolic and bariatric surgery.
-
FDA sends 30 telehealth companies warning letters over compounded GLP‑1 claims
FDA said 30 telehealth companies used false or misleading website claims for compounded GLP-1 products.
-
Obesity Society cites an uncharacterized impurity in compounded tirzepatide and B12 products
The Obesity Society called for stronger oversight after a report found an impurity in tested compounded tirzepatide and vitamin B12 combinations.
-
ZUPREME-1 topline results report up to 10.7% mean weight loss with petrelintide
Sponsor-reported phase 2 results showed up to 10.7% average weight loss at 42 weeks with investigational petrelintide, versus 1.7% with placebo.
-
Review finds no clear link between presurgical PTSD and weight loss after bariatric surgery
Nine observational studies found no statistically clear association between PTSD and weight loss after bariatric surgery, but the evidence was limited and mental health quality of life may still be worse.
-
Review finds uncertain benefit from GLP‑1 use before bariatric surgery
A 10-study meta-analysis linked preoperative GLP-1 use with modest weight reduction before surgery, but found no clear improvement in later weight loss, complications, or assessed comorbidities.
-
Small review finds weight loss after bariatric surgery in sarcopenic obesity
Seven studies involving 1,704 patients found weight and BMI reductions among people classified with sarcopenic obesity, but inconsistent definitions and imprecise safety estimates limit the conclusions.
-
Tirzepatide trial subgroup lost weight after starting medicines linked with weight gain
A post hoc analysis of three SURMOUNT trials found sizable treatment differences among participants who started medicines associated with weight gain, but the subgroup was not randomized around those added drugs.
About this publication
Reporting standards and transparency
How we report
Obesity Treatment News is a BariatricPal publication. We review the linked source material, explain what changed, and state what the evidence does not establish.
Corrections
Send factual corrections through Contact BariatricPal. Material corrections are dated and noted in the article.
Ownership and commerce
BariatricPal owns OTN and the BariatricPal Store. Pages may include clearly separated advertising or store links. Commerce does not change the source summary.
About BariatricPal · Brief author · Contact · Regulation, access, and safety · Clinical practice and outcomes